Drug
Tacrolimus（FK506）
Tacrolimus（FK506） is a pharmaceutical drug with 3 clinical trials. Currently 1 active trials ongoing.
Total Trials
3
Max Phase
—
Type
DRUG
Molecule
—
Success Metrics
Active Trials
1(33%)
Phase Distribution
Ph not_applicable
1
33%
Ph phase_4
1
33%
Phase Distribution
0
Early Stage
0
Mid Stage
1
Late Stage
Phase Distribution2 total trials
Phase 4Post-market surveillance
1(50.0%)
N/ANon-phased studies
1(50.0%)
Highest Phase Reached
Phase 4Trial Status & Enrollment
Completion Rate
0.0%
0 of 1 finished
Non-Completion Rate
100.0%
1 ended early
Currently Active
1
trials recruiting
Total Trials
3
all time
Status Distribution
Active(1)
Terminated(1)
Other(1)
Detailed Status
Withdrawn1
Recruiting1
unknown1
Development Timeline
Analytics
Development Status
Total Trials
3
Active
1
Success Rate
N/A
Most Advanced
Phase 4
Trials by Phase
Phase 41 (50.0%)
N/A1 (50.0%)
Trials by Status
withdrawn133%
recruiting133%
unknown133%
Recent Activity
1 active trials
Showing 3 of 3
recruiting
Tacrolimus and Personalized Therapy to Prevent Acute Rejection Episodes
NCT06338306
withdrawnphase_4
Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects
NCT03315052
unknownnot_applicable
The Establishment of Multiple Point Prediction Model About Tacrolimus Metabolic Differences Based on Genetic Network After Liver Transplantation and the Application of Multicenter
NCT02752529
Clinical Trials (3)
Showing 3 of 3 trials
NCT06338306
Tacrolimus and Personalized Therapy to Prevent Acute Rejection Episodes
NCT03315052Phase 4
Budesonide for Immunosuppression After Liver Transplantation to Reduce Side Effects
NCT02752529Not Applicable
The Establishment of Multiple Point Prediction Model About Tacrolimus Metabolic Differences Based on Genetic Network After Liver Transplantation and the Application of Multicenter
All 3 trials loaded
Drug Details
- Intervention Type
- DRUG
- Total Trials
- 3